Olbetam
Olbetam Uses, Dosage, Side Effects, Food Interaction and all others data.
Olbetam is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Olbetam inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Olbetam. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.
| Trade Name | Olbetam |
| Generic | Acipimox |
| Acipimox Other Names | Acipimox |
| Weight | 250mg, |
| Type | Capsule |
| Formula | C6H6N2O3 |
| Weight | Average: 154.125 Monoisotopic: 154.037842061 |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Pacific Pharmaceuticals Ltd,, Pfizer Limited |
| Available Country | Pakistan, United Kingdom, Netherlands, Switzerland |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Olbetam is a niacin derivative used in Fredrickson type IIb and type IV hyperlipoproteinemia.
Used in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood).
Olbetam is also used to associated treatment for these conditions: Fredrickson classification type IV Hyperlipidemia, Fredrickson type IIb hyperlipidemia
How Olbetam works
Olbetam inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.
Innovators Monograph
You find simplified version here Olbetam
